



COLORADO

Department of Health Care
Policy & Financing

Drug Utilization Review Board MEETING AGENDA

August 10, 2021

Open Session 1:00 pm - 5:00 pm

Zoom Link will be posted prior to the meeting at

<https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board>

Health First Colorado, Colorado's Medicaid program

DUR Board Members	CO-DUR Team
Liza Wilson Claus, PharmD (Chair) Alison Shmerling, MD, MPH (Vice Chair) Miroslav Anguelov, PharmD Todd Brubaker, DO Brian Jackson, MD, MA Shilpa Klocke, PharmD Lyle Laird, PharmD Patricia Lanius, BSPHarm, MHA Scott VanEyck, MD	Jeffrey Taylor, PharmD (HCPF) Julia Rawlings, PharmD (CO DUR) Robert L Page II, PharmD, MSPH (CO DUR) Gina Moore, PharmD, MBA (CO DUR) Heather Anderson, PhD (CO DUR) Garth Wright, MPH (CO DUR) Vanessa Patterson, MPH (CO DUR)

Call to Order

2. Roll Call and Introductions

3. Virtual Meeting Information and General Announcements

4. Colorado Department of Health Care Policy and Financing Updates

5. Final Approval of Minutes from the May 11, 2021 Meeting

6. Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest

- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

7. Clinical Updates and General Orders

- Retrospective DUR Reports
- Quarterly Module Summaries
- FDA New Product & Safety Updates
- Quarterly Drug Utilization Reports

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care
Policy & Financing

8. New Business (open for public testimony and Board review)

Proposed Criteria for PDL Drug Classes Scheduled for Review

- Anticonvulsants, Oral
- Stimulants and Related Agents
- Estrogen Agents
 - Injectable
 - Oral/Transdermal
- Contraceptives
 - Oral
 - Non-Oral
- Diabetes Management Classes
 - GLP-1 Analogues
 - Other Hypoglycemic Combinations
 - SGLT-2is & Combinations
- Glucagon Agents
- Antiplatelet Agents
- Colony Stimulating Factors
- Newer Hereditary Angioedema (HAE) Products
- Overactive Bladder (OAB) Agents

Mass review drug classes*

- Bone Resorption Suppression and Related Agents
 - Bisphosphonates
 - Non-Bisphosphonates
- Diabetes Management Classes
 - Amylin
 - Biguanides
 - DPP-4is & Combinations
 - Insulins & Related Agents
 - Meglitinides & Combinations
 - TZDs & Combinations
- GI Motility, Chronic
- Anticoagulants
 - Oral
 - Parenteral
- Erythropoiesis Stimulating Agents (ESAs)
- Prenatal Vitamins/Minerals
- Ophthalmics, Immunomodulators

Our mission is to improve health care equity, access and outcomes for the people we serve while saving Coloradans money on health care and driving value for Colorado.

<https://hcpf.colorado.gov>





COLORADO

Department of Health Care Policy & Financing

** Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria currently implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

9. Proposed ProDUR and Prior Authorization Criteria for Other Selected Products

- Aduhelm (aducanumab)
- Cablivi (caplacizumab)
- Ingrezza (valbenazine)
- Xolair (omalizumab)
- Zokinvy (lonafarnib)
- Verquvo (vericiguat)
- Myfembree (relugolix, estradiol hemihydrate, norethindrone acetate)
- Empaveli (pegcetacoplan)

10. Adjournment

Next meeting date
November 9, 2021
1:00 pm to 5:00 pm

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

